Early deaths in pediatric acute leukemia: A population-based study

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1518-1522

  Cheng, Sylvia ^a,b   Pole, Jason D ^a   Sung, Lillian ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Early deaths; Leukemia; Mortality; Ontario; Pediatric; Population based

Indexed keywords

ANTHRACYCLINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANADA; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CHILD DEATH; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; DOWN SYNDROME; FEMALE; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ADOLESCENT; HEALTH SURVEY; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; ONTARIO; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; REGISTER; TIME FACTOR;

ADOLESCENT; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; ONTARIO; POPULATION SURVEILLANCE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84903437777     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.850685     Document Type: Article

References (30)

1. Ellison LF, Pogany L, Mery LS. Childhood and adolescent cancersurvival: a period analysis of data from the Canadian Cancer Registry.Eur J Cancer 2007 ; 43 : 1967-1975.
2. Pui C H, Pei D, Pappo A S, et al. Treatment outcomes in black andwhite children with cancer: results from the SEER database and StJude Children ' s Research Hospital, 1992 through 2007. J Clin Oncol2012; 30 : 2005-2012.
3. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for childrenand adolescents with cancer: challenges for the twenty-fi rst century.J Clin Oncol 2010 ; 28 : 2625-2634.
4. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia.N Engl J Med 2006; 354: 166-178.
5. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicityby optimizing chemotherapy, but not by addition of granulocytecolony-stimulating factor in children and adolescents with acutemyeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006 ; 24 :4499-4506.
6. Ravindranath Y, Chang M, Steuber C P, et al. Pediatric OncologyGroup (POG) studies of acute myeloid leukemia (AML): a review offour consecutive childhood AML trials conducted between 1981 and2000. Leukemia 2005; 19 : 2101-2116.
7. Stevens R F, Hann I M, Wheatley K, Gray R G. Marked improvementsin outcome with chemotherapy alone in paediatric acute myeloidleukemia: results of the United Kingdom Medical Research Council ' s10th AML trial. MRC Childhood Leukaemia Working Party. Br JHaematol 1998 ; 101 : 130-140.
8. Felix CA, Lange BJ, Chessells JM. Pediatric Acute LymphoblasticLeukemia: Challenges and Controversies in 2000. Hematology Am SocHematol Educ Program 2000: 285-302.
9. Pritchard-Jones K, Dixon-Woods M, Naafs-Wilstra M, et al.Improving recruitment to clinical trials for cancer in childhood. LancetOncol 2008 ; 9 : 392-399.
10. Christensen MS, Heyman M, Mottonen M, et al. Treatmentrelateddeath in childhood acute lymphoblastic leukaemia in theNordic countries: 1992-2001. Br J Haematol 2005; 131: 50-58.
11. Blanco E, Beyene J, Maloney AM, et al. Non-relapse mortality inpediatric acute lymphoblastic leukemia: a systematic review and metaanalysis. Leuk Lymphoma 2012; 53: 878-885.
12. Greenberg ML, Barr RD, DiMonte B, et al. Childhood cancerregistries in Ontario, Canada: lessons learned from a comparison oftwo registries. Int J Cancer 2003 ; 105 : 88-91.
13. Greenberg ML, Barr RD, DiMonte B, et al. Childhood cancerregistries in Ontario, Canada: lessons learned from a comparison oftwo registries. Int J Cancer 2003 ; 105 : 88-91.
14. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicityby optimizing chemotherapy, but not by addition of granulocytecolony-stimulating factor in children and adolescents with acutemyeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006 ; 24 :4499-4506.
15. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths andtreatment-related mortality in children undergoing therapy for acutemyeloid leukemia: analysis of the multicenter clinical trials AML-BFM93 and AML-BFM 98. J Clin Oncol 2004 ; 22 : 4384-4393.
16. Atlas of Childhood Cancer in Ontario. Ontario: Pediatric OncologyGroup of Ontario; 2004.
17. Schrappe M, Reiter A, Zimmermann M, et al. Long-term resultsof four consecutive trials in childhood ALL performed by the ALL-BFMstudy group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia2000 ; 14 : 2205-2222.
18. Slats AM, Egeler RM, van der Does-van den Berg A, et al.Causes of death-other than progressive leukemia-in childhoodacute lymphoblastic (ALL) and myeloid leukemia (AML): the DutchChildhood Oncology Group experience. Leukemia 2005 ; 19 : 537-544.
19. Christensen MS, Heyman M, Mottonen M, et al. Treatmentrelateddeath in childhood acute lymphoblastic leukaemia in theNordic countries: 1992-2001. Br J Haematol 2005; 131: 50-58.
20. Hargrave D R, Hann, II, Richards S M, et al. Progressive reductionin treatment-related deaths in Medical Research Council childhoodlymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, XandXI). Br J Haematol 2001 ; 112 : 293-299.
21. Rubnitz J E, Lensing S, Zhou Y, et al. Death during inductiontherapy and fi rst remission of acute leukemia in childhood: the St. Judeexperience. Cancer 2004 ; 101 : 1677-1684.
22. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapyof acute lymphoblastic leukemia can decrease treatment burdenand improve survival: treatment results of 2169 unselected pediatricand adolescent patients enrolled in the trial ALL-BFM 95. Blood2008 ; 111 : 4477-4489.
23. Kavcic M, Fisher BT, Li Y, et al. Induction mortality and resourceutilization in children treated for acute myeloid leukemia at free-standingpediatric hospitals in the United States. Cancer 2013; 119: 1916-1923.
24. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths andtreatment-related mortality in children undergoing therapy for acutemyeloid leukemia: analysis of the multicenter clinical trials AML-BFM93 and AML-BFM 98. J Clin Oncol 2004 ; 22 : 4384-4393.
25. Hargrave D R, Hann, II, Richards S M, et al. Progressive reductionin treatment-related deaths in Medical Research Council childhoodlymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, XandXI). Br J Haematol 2001 ; 112 : 293-299.
26. Wheeler K, Chessells JM, Bailey CC, et al. Treatment relateddeaths during induction and in fi rst remission in acute lymphoblasticleukaemia: MRC UKALL X. Arch Dis Child 1996 ; 74 : 101-107.
27. Prucker C, Attarbaschi A, Peters C, et al. Induction death andtreatment-related mortality in fi rst remission of children with acutelymphoblastic leukemia: a population-based analysis of the AustrianBerlin-Frankfurt-Munster study group. Leukemia 2009; 23: 1264-1269.
28. Tran TH, Mitchell D, Dix D, et al. Infections in children with Downsyndrome and acute myeloid leukemia: a report from the CanadianInfections in AML Research Group. Infectious Agents and Cancer2013 ;(in press).
29. Sung L, Aplenc R, Alonzo TA, et al. Predictors and short-termoutcomes of hyperleukocytosis in children with acute myeloidleukemia: a report from the Children ' s Oncology Group. Haematologica2012 ; 97 : 1770-1773.
30. Ethier MC, Blanco E, Lehrnbecher T, et al. Lack of clarity in thedefi nition of treatment-related mortality: pediatric acute leukemiaand adult acute promyelocytic leukemia as examples. Blood 2011 ; 118 :5080-5083.